Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lymphoma drug combo trial halted early

NCT ID NCT04425070

Disease control Sponsor: Antengene Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called selinexor combined with chemotherapy or another drug (tislelizumab) in people with relapsed or hard-to-treat T and NK cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so results are limited. It was not a cure, but aimed to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

56 people

The number who actually took part.

Started

Aug 2020

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The patient is willing to provide written ICF. 2. Age≥ 18 years. 3. R/R PTCL and NK/T-cell lymphoma as confirmed by histological methods according to WHO classification of tumors of lymphoid tissues 2016. 4. Previously received at least one or more standard regimens including anthracycline. 5. Recurrence or the recurrence disease after the last treatment completed. 6. At least one measurable disease per modified efficacy assessment criteria (Cheson 2014). 7. ECOG PS 0 or 1. 8. Any toxicity caused by previously anti-tumor therapy must recovered to ≤ Grade 1 (NCI-CTCAE v5.0) with exception of hearing loss, alopecia, and pigmentation. 9. Expected life time longer than 3 months. Exclusion Criteria: 1. Current have disease or history of central nervous system lymphoma. 2. HBV-DNA positive, or HCV-RNA positive. 3. Patients with a known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome. 4. Received major surgery within 4 weeks of first dose of study drug 5. Known received SINE, including ATG-010. 6. Unable to swallow the tablets, suffers from malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may interfere with ATG-010 absorption. 7. Known allergy to ATG-010, or ICE, or GEMOX. 8. A woman who is pregnant or nursing. 9. The investigator considerations on patient's complications or other conditions may affect protocol compliance or may be inappropriate for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NK T-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NK T-cell lymphoma Peripheral T-cell lymphoma

Contacts and locations

Locations

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, 230031, China

  • Beijing Tongren Hospital.CMU

    Beijing, Beijing Municipality, 100005, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, 530021, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, 210000, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • Tianjin Medical Universisity Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.